{"url_path":"/sec/tenx/10-q/2026/item-6","section_key":"item-6","section_title":"Item 6 EXHIBITS","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-12","source_url":"https://www.sec.gov/Archives/edgar/data/34956/0001193125-26-219383-index.html","accession_number":"0001193125-26-219383","cik":"0000034956","ticker":"TENX","issuer_name":"TENAX THERAPEUTICS, INC.","edgar_url":"https://www.sec.gov/Archives/edgar/data/34956/0001193125-26-219383-index.html","primary_entity_key":"0000034956","primary_entity_name":"TENAX THERAPEUTICS, INC."},"word_count":360,"has_tables":true,"body_markdown":"ITEM 6. EXHIBITS\n\nThe following exhibits are being filed or furnished as part of this Quarterly Report on Form 10-Q and are numbered in accordance with Item 601 of Regulation S-K:\n\nExhibit\n\nNumber\n\nDescription\n\n[10.1+](https://www.sec.gov/Archives/edgar/data/34956/000165495426000232/tennx_ex101.htm)\n\n \n\n[Second Amendment to Executive Employment Agreement by and between Tenax Therapeutics, Inc. and Stuart Rich, MD, dated January 6, 2026 (incorporated by reference to Exhibit 10.1 to the Company’s Form 8-K filed with the SEC on January 9, 2026).](https://www.sec.gov/Archives/edgar/data/34956/000165495426000232/tennx_ex101.htm)\n\n[10.2+](https://www.sec.gov/Archives/edgar/data/34956/000119312526168521/d81080dex101.htm)\n\n \n\n[Executive Employment Agreement with Thomas R. Staab, II, dated April 9, 2026 (incorporated by reference to Exhibit 10.1 to the Company’s Form 8-K filed with the SEC on April 22, 2026).](https://www.sec.gov/Archives/edgar/data/34956/000119312526168521/d81080dex101.htm)\n\n[10.3+](https://www.sec.gov/Archives/edgar/data/34956/000119312526168521/d81080dex102.htm)\n\n \n\n[Form of Inducement Restricted Stock Unit Award Agreement (incorporated by reference to Exhibit 10.2 to the Company’s Form 8-K filed with the SEC on April 22, 2026).](https://www.sec.gov/Archives/edgar/data/34956/000119312526168521/d81080dex102.htm)\n\n[31.1*](tennx-ex31_1.htm)\n\n[Certification of President and Chief Executive Officer pursuant to Section 302 of the Sarbanes Oxley Act of 2002.](tennx-ex31_1.htm)\n\n[31.2*](tennx-ex31_2.htm)\n\n[Certification of Principal Financial Officer and Principal Accounting Officer pursuant to Section 302 of the Sarbanes Oxley Act of 2002.](tennx-ex31_2.htm)\n\n[32.1**](tennx-ex32_1.htm)\n\n[Certification of President and Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.](tennx-ex32_1.htm)\n\n[32.2**](tennx-ex32_2.htm)\n\n[Certification of Principal Financial Officer and Principal Accounting Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.](tennx-ex32_2.htm)\n\n101*\n\nInline XBRL Document Set for the condensed consolidated financial statements and accompanying notes in Part I, Item 1, “Financial Statements” of this Quarterly Report on Form 10-Q.\n\n104*\n\nInline XBRL for the cover page of this Quarterly Report on Form 10-Q, included in the Exhibit 101 Inline XBRL Document Set.\n\n+ Management contract or compensatory plan.\n\n* Filed herewith\n\n** Furnished herewith\n\n22\n\n[Table of Contents](#toc_page)\n\n \n\nSIGNATURES\n\nPursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.\n\nDate: May 12, 2026\n\n \n\n \n\nTENAX THERAPEUTICS, INC.\n\n \n\n \n\n \n\n \n\n \n\n \n\nBy:\n\n/s/ Christopher T. Giordano\n\n \n\n \n\n \n\nChristopher T. Giordano\n\n \n\n \n\n \n\nPresident and Chief Executive Officer\n\n \n\n \n\n \n\n \n\n \n\n \n\nBy:\n\n /s/ Thomas A. McGauley\n\n \n\n \n\n \n\nThomas A. McGauley\n\n \n\n \n\n \n\nPrincipal Financial Officer and Principal Accounting Officer\n\n \n\n \n\n23"}